The prohibitin 3′ untranslated region polymorphism is not associated with risk of ovarian cancer

Gynecologic Oncology

Volumn 90, Issue 1, 2003, Pages 145-149

  Spurdle, Amanda B ^a   Purdie, David M ^a   Chen, Xiaoqing ^a   Chenevix Trench, Georgia ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Ovarian cancer; Polymorphism; prohibitin

Indexed keywords

PROTEIN P53; PROHIBITIN; PROTEIN; REPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ADULT; AGED; ALLELIC EXCLUSION; ARTICLE; AUSTRALIA; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CELL HETEROGENEITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; GENETIC CODE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; OVARY TUMOR; RISK FACTOR;

3' UNTRANSLATED REGIONS; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROTEINS; REPRESSOR PROTEINS; RISK FACTORS;

EID: 0038500734     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00193-8     Document Type: Article

References (19)

1. Berchuck A., Kohler M.F., Marks J.R., Wiseman R., Boyd J., Bast Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol. 170:1994;246-252.
2. Jupe E.R., Liu X.T., Kiehlbauch J.L., McClung J.K., Dell'Orco R.T. Prohibitin in breast cancer cell lines loss of antiproliferative activity is linked to 3′ untranslated region mutations . Cell Growth Differ. 7:1996;871-878.
3. Jupe E.R., Badgett A.A., Neas B.R., Craft M.A., Mitchell D.S., Resta R., et al. Single nucleotide polymorphism in prohibitin 39 untranslated region and breast-cancer susceptibility. Lancet. 357:2001;1588-1589.
4. Chenevix-Trench G., Kerr J., Hurst T., Shih Y.C., Purdie D., Bergman L., et al. Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms clinicopathological correlations . Genes Chromosomes Cancer. 18:1997;75-83.
5. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature. 417:2002;949-954.
6. Risch H.A., Marrett L.D., Jain M., Howe G.R. Differences in risk factors for epithelial ovarian cancer by histologic type results of a case-control study . Am J Epidemiol. 144:1996;363-372.
7. Kvale G., Heuch I., Nilssen S., Beral V. Reproductive factors and risk of ovarian cancer a prospective study . Int J Cancer. 42:1988;246-251.
8. Ichikawa Y., Nishida M., Suzuki H., Yoshida S., Tsunoda H., Kubo T., et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. [published erratum appears in Cancer Res 1994 Mar 1;54(5):1391] Cancer Res. 54:1994;33-35.
9. Obata K., Morland S.J., Watson R.H., Hitchcock A., Chenevix Trench G., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58:1998;2095-2097.
10. Purdie D.M., Bain C.J., Siskind V., Russell P., Hacker N.F., Ward B.G., et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer. 81:1999;559-563.
11. Marchbanks P.A., Wilson H., Bastos E., Cramer D.W., Schildkraut J.M., Peterson H.B. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol. 95:2000;255-260.
12. Purdie D., Green A., Bain C., Siskind V., Ward B., Hacker N., et al. Reproductive and other factors and risk of epithelial ovarian cancer an Australian case-control study. Survey of Women's Health Study Group . Int J Cancer. 62:1995;678-684.
13. Pettersson F. Annual Report on Gynaecologic Cancer of FIGO. 1988;Panorama Press, Stockholm.
14. Webb P.M., Green A., Cummings M.C., Purdie D.M., Walsh M.D., Chenevix Trench G. Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst. 90:1998;1729-1734.
15. Spurdle A.B., Chen X.Q., Abbazadegan M., Martin N., Khoo S.K., Hurst T., et al. CYP17 promotor polymorphism and ovarian cancer risk. Int J Cancer. 86:2000;436-439.
16. Heath A.C., Bucholz K.K., Madden P.A., Dinwiddie S.H., Slutske W.S., Bierut L.J., et al. Genetic and environmental contributions to alcohol dependence risk in a national twin sample consistency of findings in women and men . Psychol Med. 27:1997;1381-1396.
17. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1988;1215.
18. Levi S., Urbano Ispizua A., Gill R., Thomas D.M., Gilbertson J., Foster C., Marshall C.J. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 51:1991;3497-3502.
19. Spurdle A.B., Hopper J.L., Chen X., McCredie M.R., Giles G.G., Newman B., Chenevix-Trench G. Prohibitin 3′ untranslated region polymorphism breast cancer risk in Australian women. Lancet. 360:2002;925-926.